Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 25:17:1219-1230.
doi: 10.2147/TCRM.S303057. eCollection 2021.

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease

Honeylen Maryl Teo  1 , Terry J Smith  2   3 , Shannon S Joseph  2
Affiliations
Review

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease

Honeylen Maryl Teo et al. Ther Clin Risk Manag. .

Abstract

Thyroid eye disease (TED; also known as thyroid-associated ophthalmopathy) is an autoimmune condition with disabling and disfiguring consequences. Teprotumumab is the first and only medication approved by the United States Food and Drug Administration for the treatment of TED. We review the efficacy and safety of teprotumumab in TED, highlighting results from the 2 randomized, double-masked, placebo-controlled trials. Post-approval case reports of teprotumumab use in patients with compressive optic neuropathy (CON) and inactive TED were similarly favorable to those from the trials. The preliminarily results of teprotumumab for CON and inactive TED should be investigated in formal clinical trials. Teprotumumab should be avoided in pregnancy. Evidence also suggests that teprotumumab may exacerbate pre-existing inflammatory bowel disease, worsen hyperglycemia, and be associated with hearing impairment. Patients at risk for these adverse events need to be closely monitored with baseline and periodic assessments.

Keywords: Graves’ ophthalmopathy; anti-IGF-IR; autoimmune; monoclonal antibody; thyroid-associated ophthalmopathy.

PubMed Disclaimer

Conflict of interest statement

Dr. Terry J. Smith has been issued the following US patents, held by University of California Los Angeles and Los Angeles Biomedical Institute and covering the use of insulin-like growth factor I receptor inhibition and teprotumumab in Graves’ disease and other autoimmune diseases: 6936426, 7998681, 8153121, and 8178304. He receives consulting fees from Horizon Therapeutics and Immunovant outside the submitted work. His institution received research support from Horizon Therapeutics for participating in the clinical trials of teprotumumab for TED. Dr. Shannon S. Joseph receives consulting fees from Horizon Therapeutics outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Smith TJ, Laszlo H. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra1510030 - DOI - PubMed
    1. Shan SJC, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–185. doi:10.1097/WNO.0000000000000132 - DOI - PubMed
    1. Tsui S, Naik V, Hoa N, et al. Evidence for an association between TSH and IGF-1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397–4405. doi:10.4049/jimmunol.181.6.4397 - DOI - PMC - PubMed
    1. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology. 2011;118(11):2279–2285. doi:10.1016/j.ophtha.2011.03.030 - DOI - PubMed
    1. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab. 2010;95(5):2123–2131. doi:10.1210/jc.2009-2470 - DOI - PubMed